-
1
-
-
0003306666
-
The antiplatelet activity of clopidogrel is inhibited by atorvastatin but not by pravastatin
-
Abstract 2086
-
Lau WC, Waskell LA, Neer CJ, Carville DGM, Bates ER. The antiplatelet activity of clopidogrel is inhibited by atorvastatin but not by pravastatin. Circulation 2000;102 (supl): II-429. Abstract 2086
-
(2000)
Circulation
, vol.102
, Issue.SUPPL.
-
-
Lau, W.C.1
Waskell, L.A.2
Neer, C.J.3
Carville, D.G.M.4
Bates, E.R.5
-
2
-
-
0037422534
-
Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation. A new drug-drug interaction
-
Lau WC, Waskell LA, Watkins PB, Neer CJ, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation. A new drug-drug interaction. Circulation 2003;107:32-7.
-
(2003)
Circulation
, vol.107
, pp. 32-37
-
-
Lau, W.C.1
Waskell, L.A.2
Watkins, P.B.3
Neer, C.J.4
-
3
-
-
0035124920
-
Platelet-active drugs. The relationship among dose, effectiveness, and side effects
-
Patrono C, Coller B, Dalen JE, FitzGerald GA, et al. Platelet-active drugs. The relationship among dose, effectiveness, and side effects. Chest 2001;119:39S-63S.
-
(2001)
Chest
, vol.119
-
-
Patrono, C.1
Coller, B.2
Dalen, J.E.3
FitzGerald, G.A.4
-
5
-
-
0042937918
-
Antiplatelet and antithrombotic drugs
-
Frishman WH, Sonnenblick EH, Sica DA, eds. New YorK: McGraw-Hill
-
Frishman WH, Lerner RG, Klein MD, Roganovic M. Antiplatelet and antithrombotic drugs. In: Frishman WH, Sonnenblick EH, Sica DA, eds. Cardiovascular Therapeutics, 2nd edition. New YorK: McGraw-Hill, 2003;259-99.
-
(2003)
Cardiovascular Therapeutics, 2nd Edition
, pp. 259-299
-
-
Frishman, W.H.1
Lerner, R.G.2
Klein, M.D.3
Roganovic, M.4
-
6
-
-
0038508970
-
The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin
-
Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Disp 2003;31:53-9.
-
(2003)
Drug Metab Disp
, vol.31
, pp. 53-59
-
-
Clarke, T.A.1
Waskell, L.A.2
-
7
-
-
0028083293
-
The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A
-
Savi P, Combalbert J, Gaich C, Rouchon MC, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 1994;72:313-7.
-
(1994)
Thromb Haemost
, vol.72
, pp. 313-317
-
-
Savi, P.1
Combalbert, J.2
Gaich, C.3
Rouchon, M.C.4
-
8
-
-
0034805389
-
P2Y12, a new platelet ADP receptor, target of clopidogrel
-
Savi P, Labouret C, Guette F, Lupker J, Herbert JM. P2Y12, a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Com 2001;283:379-83.
-
(2001)
Biochem Biophys Res Com
, vol.283
, pp. 379-383
-
-
Savi, P.1
Labouret, C.2
Guette, F.3
Lupker, J.4
Herbert, J.M.5
-
10
-
-
0041434851
-
Clopidogrel nonresponders discovered during point-of-care platelet aggregation testing
-
abstract 1009-117
-
Lau WC, Neer CJ, Watkins PB, Carville DG, et al. Clopidogrel nonresponders discovered during point-of-care platelet aggregation testing. JACC 2003;41 (6; suppl A): 225A (abstract 1009-117).
-
(2003)
JACC
, vol.41
, Issue.6 SUPPL. A
-
-
Lau, W.C.1
Neer, C.J.2
Watkins, P.B.3
Carville, D.G.4
-
11
-
-
0037382774
-
Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested
-
Serebruany VL, Steinhubl SR, Hennekens CH. Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested (editorial). Circulation 2003;107:1568-9.
-
(2003)
Circulation
, vol.107
, pp. 1568-1569
-
-
Serebruany, V.L.1
Steinhubl, S.R.2
Hennekens, C.H.3
-
14
-
-
0041936209
-
Platelet aggregation
-
Michelson AD, ed. Amsterdam: Academic Press
-
Refaai MA, Laposata M. Platelet aggregation. In: Michelson AD, ed. Platelets. Amsterdam: Academic Press 2002;291-6.
-
(2002)
Platelets
, pp. 291-296
-
-
Refaai, M.A.1
Laposata, M.2
-
15
-
-
0041434848
-
Evaluation of a BED-SIDE platelet function assay: Performance and clinical utility
-
Lau WC, Walker T, Ogilby D, Walsh MM, Carville DGM, Guyer KE, Bates ER. Evaluation of a BED-SIDE platelet function assay: performance and clinical utility. Ann Cardiac Anesth 2002;5:33-42.
-
(2002)
Ann Cardiac Anesth
, vol.5
, pp. 33-42
-
-
Lau, W.C.1
Walker, T.2
Ogilby, D.3
Walsh, M.M.4
Carville, D.G.M.5
Guyer, K.E.6
Bates, E.R.7
-
16
-
-
0017902733
-
Quantification of the morphological reaction of platelets to aggregating agents and of its reversal by aggregation inhibitors
-
Born GV, Dearnley R, Foulks JG, Sharp DE. Quantification of the morphological reaction of platelets to aggregating agents and of its reversal by aggregation inhibitors. J Physiol 1978;280:193-212.
-
(1978)
J Physiol
, vol.280
, pp. 193-212
-
-
Born, G.V.1
Dearnley, R.2
Foulks, J.G.3
Sharp, D.E.4
-
17
-
-
0033007420
-
Inibidores da redutase do HMG-CoA: Breve revisao das suas propriedades farmacológicas e eficácia clínica na doença cardiovascular
-
Marques da Silva P. Inibidores da redutase do HMG-CoA: breve revisao das suas propriedades farmacológicas e eficácia clínica na doença cardiovascular. Rev Port Cardiol 1999;18:65-76.
-
(1999)
Rev Port Cardiol
, vol.18
, pp. 65-76
-
-
Marques da Silva, P.1
-
18
-
-
0042937903
-
Estatinas: Acçoes farmacológicas e características farmacocinéticas
-
Marques da Silva P. Estatinas: acçoes farmacológicas e características farmacocinéticas. Rev FML 1999;4 (supl. 5): 33-44.
-
(1999)
Rev FML
, vol.4
, Issue.SUPPL. 5
, pp. 33-44
-
-
Marques da Silva, P.1
-
19
-
-
0033852714
-
The value of reporting therapeutic ineffectiveness as an adverse drug reaction
-
Meyboom RHB, Lindquist M, Flygare AK, Biriell C, Edwards IR. The value of reporting therapeutic ineffectiveness as an adverse drug reaction. Drug Saf 2000;23:95-9.
-
(2000)
Drug Saf
, vol.23
, pp. 95-99
-
-
Meyboom, R.H.B.1
Lindquist, M.2
Flygare, A.K.3
Biriell, C.4
Edwards, I.R.5
-
20
-
-
0034750164
-
Satins do not affect platelet inhibition with clopidogrel during coronary stenting
-
Serebruany VL, Malinin AI, Callahan KP, Gurbel PA, Steinhubl SR. Satins do not affect platelet inhibition with clopidogrel during coronary stenting. Atherosclerosis 2001;159:239-41.
-
(2001)
Atherosclerosis
, vol.159
, pp. 239-241
-
-
Serebruany, V.L.1
Malinin, A.I.2
Callahan, K.P.3
Gurbel, P.A.4
Steinhubl, S.R.5
-
21
-
-
0037326063
-
Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: The Plavix Reduction of New Thrombus Occurrence (PRONTO) trial
-
Gubel PA, Cummings CC, Bell CR, Alford AB, Meister AF, Serebruany VL. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction of New Thrombus Occurrence (PRONTO) trial. Am Heart J 2003;145:239-47.
-
(2003)
Am Heart J
, vol.145
, pp. 239-247
-
-
Gubel, P.A.1
Cummings, C.C.2
Bell, C.R.3
Alford, A.B.4
Meister, A.F.5
Serebruany, V.L.6
-
22
-
-
0041936203
-
Six-month mortality ratyes are lower in patients with an acute coronary syndrome treated with the combination of clopidogrel and a statin than in patients treated with either therapy alone: An analysis from the Global Registry of Acute Coronary Events
-
abstract 822-3
-
Lim MJ, Spencer FA, Gore JM, Dabbous OH et al. Six-month mortality ratyes are lower in patients with an acute coronary syndrome treated with the combination of clopidogrel and a statin than in patients treated with either therapy alone: an analysis from the Global Registry of Acute Coronary Events. JACC 2003;41 (6 supl A): 361A (abstract 822-3).
-
(2003)
JACC
, vol.41
, Issue.6 SUPPL. A
-
-
Lim, M.J.1
Spencer, F.A.2
Gore, J.M.3
Dabbous, O.H.4
-
23
-
-
0000210136
-
Complementary additive benefit of clopidogrel and lipid-lowering therapy in patients with atherosclerosis
-
abstract 906-5
-
Bhatt DL, Foody JM, Hirsch AT, Ringleb P, Hacks W, Topol EJ. Complementary additive benefit of clopidogrel and lipid-lowering therapy in patients with atherosclerosis. JACC 2000;35 (2 supl A):326A (abstract 906-5).
-
(2000)
JACC
, vol.35
, Issue.2 SUPPL. A
-
-
Bhatt, D.L.1
Foody, J.M.2
Hirsch, A.T.3
Ringleb, P.4
Hacks, W.5
Topol, E.J.6
-
24
-
-
0037465436
-
Early and late effects of clopidogrel in patients with acute coronary syndromes
-
Yusuf S, Mehta SR, Zhao F, Gersh BJ, Commerford PJ, et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003;107:966-72.
-
(2003)
Circulation
, vol.107
, pp. 966-972
-
-
Yusuf, S.1
Mehta, S.R.2
Zhao, F.3
Gersh, B.J.4
Commerford, P.J.5
-
25
-
-
0036283175
-
Interaction between aspirin and ACE inhibitors: Resolving discrepancies using a meta-analysis
-
Takkouche B, Etminan M, Caamano F, Rochon PA. Interaction between aspirin and ACE inhibitors: resolving discrepancies using a meta-analysis. Drug Saf 2002;25:373-8.
-
(2002)
Drug Saf
, vol.25
, pp. 373-378
-
-
Takkouche, B.1
Etminan, M.2
Caamano, F.3
Rochon, P.A.4
-
26
-
-
0041434845
-
-
Atorvastatin does not affect the antiplatelet properties os clopidogrel in patients undergoing coronary stenting in randomized data from the Interaction of Atorvastatin and Clopidogrel (INTERACTION) trial. Poster presented. March 30 - April 2, Chicago, Illinois, USA
-
Serebruany V, Midei M, Malinin, Oshrine BR, Lowry DR, et al. Atorvastatin does not affect the antiplatelet properties os clopidogrel in patients undergoing coronary stenting in randomized data from the Interaction of Atorvastatin and Clopidogrel (INTERACTION) trial. Poster presented at ACC' 03 - 52nd Annual Scientific Session. March 30 - April 2, 2003, Chicago, Illinois, USA.
-
(2003)
ACC' 03 - 52nd Annual Scientific Session
-
-
Serebruany, V.1
Midei, M.2
Malinin3
Oshrine, B.R.4
Lowry, D.R.5
|